Browse studies

Find your next paid study

1 recruiting study matching your filters

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies …

Solid Tumor, AdultRefractory CancerEndometrial Carcinoma (EC)+4 more

GV20 TherapeuticsNCT05669430